Kasper Aaboe

GLP‐1: physiological effects and potential therapeutic applications

J. Holst, S. Madsbad, K. Aaboe, 2008, Diabetes, obesity & metabolism.

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity

J. Holst, T. Vilsbøll, F. Knop, 2012, Diabetes, obesity & metabolism.

Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes

J. Holst, M. Christensen, T. Vilsbøll, 2010, Regulatory Peptides.

Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes

J. Holst, J. Henriksen, S. Madsbad, 2012, Diabetologia.

Twelve weeks treatment with the DPP‐4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non‐glucose induced insulin secretion in patients with type 2 diabetes mellitus

J. Holst, T. Vilsbøll, F. Knop, 2010, Diabetes, obesity & metabolism.

Dexamethasone affects human fetal adrenal steroidogenesis and subsequent ACTH response in an ex vivo culture model

H. Frederiksen, R. Mitchell, K. Aaboe, 2023, Frontiers in endocrinology.

KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

J. Holst, T. Vilsbøll, F. Knop, 2009, The Journal of clinical endocrinology and metabolism.